Sermorelin

Sermorelin is a synthetic analogue of growth hormone–releasing hormone (GHRH) used in laboratory research to investigate signaling within the hypothalamic–pituitary somatotropic axis. In preclinical systems, GHRH-family peptides are applied to interrogate receptor binding, second-messenger signaling, and downstream transcriptional responses associated with growth hormone (GH) secretion dynamics and GH-linked signaling networks.
Experimental interest in sermorelin spans endocrine signaling, neuroendocrine regulation, and tissue-level remodeling signatures characterized in controlled in-vitro experiments and in-vivo animal models. All descriptions on this page are presented strictly for research contexts and do not imply any diagnostic, medical, or clinical use.

Biochemical Characteristics
Sequence: Tyr-DL-Ala-DL-Asp-DL-Ala-DL-xiIle-DL-Phe-DL-xiThr-DL-Asn-DL-Ser-DL-Tyr-DL-Arg-DL-Lys-DL-Val-DL-Leu-Gly-DL-Gln-DL-Leu-DL-Ser-DL-Ala-DL-Arg-DL-Lys-DL-Leu-DL-Leu-DL-Gln-DL-Asp-DL-xiIle-DL-Met-DL-Ser-DL-Arg

Molecular Formula: C149H246N44O42S

Molecular Weight: 3357.933 g/mol

PubChem CID: 16129620
As a GHRH-family peptide analogue, sermorelin is used in biochemical workflows to evaluate ligand–receptor interactions, sequence–activity relationships, and stability/handling variables relevant to experimental design. Functional readouts are commonly generated in cell-based assays (e.g., receptor activation and downstream signaling) or in animal models where endocrine-axis activity can be quantified via established laboratory endpoints.

Research Applications

Sermorelin is supplied for research workflows that may include (non-exhaustive):

GHRH receptor (GHRHR) pharmacology, including ligand binding and receptor-selectivity studies
cAMP/PKA signaling and downstream transcriptional regulation in somatotroph-derived or engineered receptor-expression systems
GH/IGF-axis pathway mapping in controlled preclinical models (molecular and tissue-level endpoints)
Neuroendocrine signaling studies assessing hypothalamic peptide networks and sleep/feeding-related signaling mediators
Exploratory in-vivo model work evaluating remodeling signatures (e.g., extracellular matrix turnover, angiogenesis markers, and inflammatory mediator profiles) under controlled experimental conditions

Pathway / Mechanistic Context

Mechanistically, GHRH-family ligands signal through the growth hormone–releasing hormone receptor (GHRHR), a class B G protein–coupled receptor. In canonical models, receptor engagement is associated with activation of adenylate cyclase and elevation of intracellular cAMP, supporting PKA-dependent phosphorylation events and regulated gene expression programs relevant to somatotroph function.
Downstream signaling contexts frequently evaluated in preclinical systems include pathway cross-talk with MAPK/ERK and PI3K/Akt signaling nodes, which are commonly studied for their roles in cell survival, differentiation programs, and stimulus-dependent transcriptional outputs. In tissue models, downstream readouts may include extracellular matrix (ECM) turnover markers, vascular remodeling/angiogenesis signatures, and cytokine/chemokine profiles measured using standard laboratory assays.

Preclinical Research Summary

GHRH-Analogue Signaling in Cardiac Remodeling Models
Preclinical large-animal studies have evaluated GHRH-analogue signaling in controlled ischemic injury models. Reported experimental endpoints include remodeling-associated measures such as apoptosis-associated markers, extracellular matrix organization, and microvascular/capillary density in peri-injury tissue regions, along with inflammatory mediator profiling in myocardial tissue1, 2.
These investigations are typically used to inform mechanistic remodeling biology experiments (e.g., ECM deposition/turnover, angiogenesis-related gene expression, and inflammatory signaling changes) in vitro and in vivo, and are presented here solely as preclinical pathway context.
GHRH-Analogue Activity in Experimental Seizure Models
Rodent epilepsy models have been used to explore interactions between GHRH analogues and inhibitory neurotransmission systems. Published work has examined relationships between GHRH-family signaling and GABA receptor biology in brain tissue and experimental seizure paradigms, supporting mechanistic evaluation of receptor cross-talk in neurophysiological signaling networks3.
Neuroendocrine Axis Coupling in Sleep-Related Signaling
Sleep–wake regulatory pathways are frequently investigated through neuropeptide systems, including orexin/hypocretin networks. In fish models, studies have assessed endocrine coupling between GHRH-axis activity and orexigenic signaling, providing a basis for mechanistic experiments examining neuroendocrine coordination and peptide–receptor signaling integration under controlled laboratory conditions4.
Receptor Regulation and Desensitization Concepts in Peptide Signaling
Experimental frameworks for peptide ligands frequently assess receptor regulation phenomena (e.g., desensitization, internalization, and signaling bias) using established in-vitro models and systems-level readouts. Literature discussing receptor response dynamics and tachyphylaxis/desensitization concepts is frequently used to inform receptor pharmacology experiment design and interpretation of longitudinal signaling measurements in controlled settings5, 6.
All research summaries above reflect preclinical and laboratory observations and are provided solely to support experimental planning and mechanistic discussion.

Form & Analytical Testing

Sermorelin supplied for research is typically prepared as a synthetic peptide for laboratory handling and downstream analytical verification. Product identity and purity are commonly confirmed using chromatographic and mass spectrometric methods. Batch-specific analytical documentation is provided below.